Immuneering Corp is a late stage clinical oncology company focused on developing and commercializing Deep Cyclic Inhibitors a novel class of anti cancer medicines. The company targets the mitogen activated protein kinase MAPK pathway and other core signaling pathways to improve durability and tolerability of cancer therapies. Its lead product candidate atebimetinib is an oral once daily inhibitor of MEK designed to provide cyclic inhibition of the MAPK pathway. Immuneering…
Immuneering Corp is a late stage clinical oncology company focused on developing and commercializing Deep Cyclic Inhibitors a novel class of anti cancer medicines. The company targets the mitogen activated protein kinase MAPK pathway and other core signaling pathways to improve durability and tolerability of cancer therapies. Its lead product candidate atebimetinib is an oral once daily inhibitor of MEK designed to provide cyclic inhibition of the MAPK pathway. Immuneering also advances a second clinical stage program called envometinib and conducts early discovery research on other signaling pathways.
Immuneering generates revenue primarily through fees for translational bioinformatics analyses performed for pharmaceutical and biotechnology partners. The company has provided services such as analyzing ibrutinib ipilimumab daratumumab glatiramer acetate and pridopidine for its collaborators. In addition Immuneering expects to receive license fees royalties or milestones if its product candidates advance to commercialization. Currently the company does not have product sales or a commercial distribution network.
Immuneering positions itself as an innovator in the oncology therapeutics space by pursuing a distinct mechanism called Deep Cyclic Inhibition that aims to normalize signaling dynamics rather than achieve chronic pathway blockade. The company faces competition from larger pharmaceutical firms developing traditional MEK inhibitors such as those marketed by Pfizer and Novartis as well as from biotechs pursuing KRAS directed therapies like Amgen and Mirati Therapeutics. Immuneering believes its proprietary bioinformatics platform and three dimensional tumor modeling give it a competitive edge in identifying drug candidates with improved efficacy and reduced toxicity.
Immuneering serves pharmaceutical and biotechnology companies that seek expertise in translational bioinformatics and tumor modeling. Specific partners mentioned in its filings include Johnson & Johnson for ibrutinib and daratumumab Bristol Myers Squibb for ipilimumab Teva for glatiramer acetate and Prilenia Therapeutics for pridopidine. The company also collaborates with Regeneron Pharmaceuticals on clinical supply of Libtayo and with Eli Lilly and Company on clinical supply of olomorasib.